230 related articles for article (PubMed ID: 24435770)
21. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria.
Le Roux PY; Gastinne T; Le Gouill S; Nowak E; Bodet-Milin C; Querellou S; Mahe B; Dubruille V; Blin N; Salaun PY; Bodere-Kraeber F
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1064-71. PubMed ID: 21308370
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
[TBL] [Abstract][Full Text] [Related]
23. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL).
Luminari S; Biasoli I; Versari A; Rattotti S; Bottelli C; Rusconi C; Merli F; Spina M; Ferreri AJ; Zinzani PL; Gallamini A; Franceschetto A; Boccomini C; Franceschetti S; Salvi F; Raimondo FD; Carella AM; Micol Q; Balzarotti M; Musto P; Federico M
Ann Oncol; 2014 Feb; 25(2):442-7. PubMed ID: 24412823
[TBL] [Abstract][Full Text] [Related]
24. The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma.
Lu Z; Lin M; Downe P; Chong S; Ling S
Ann Nucl Med; 2014 Oct; 28(8):805-11. PubMed ID: 25008291
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
26. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract][Full Text] [Related]
27. Clinical and biological prognostic factors in follicular lymphoma patients.
Jóna Á; Kenyeres A; Barna S; Illés Á; Simon Z
PLoS One; 2022; 17(8):e0272787. PubMed ID: 35925993
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
Qiao W; Zhao J; Wang C; Wang T; Xing Y
Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
[TBL] [Abstract][Full Text] [Related]
29. Follicular Lymphoma Treated with First-Line Immunochemotherapy: A Review of PET/CT in Patients Who Did Not Achieve a Complete Metabolic Response in the GALLIUM Study.
Barrington SF; Mir F; El-Galaly TC; Knapp A; Nielsen TG; Sahin D; Wenger M; Kostakoglu L; Trotman J; Meignan M
J Nucl Med; 2022 Aug; 63(8):1149-1154. PubMed ID: 34857656
[TBL] [Abstract][Full Text] [Related]
30. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers CR; Zelenetz AD; Dawson KL; Reid E
Leuk Lymphoma; 2017 Apr; 58(4):809-815. PubMed ID: 27562750
[TBL] [Abstract][Full Text] [Related]
31. Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma.
Afaq A; Fraioli F; Sidhu H; Wan S; Punwani S; Chen SH; Akin O; Linch D; Ardeshna K; Lambert J; Miles K; Groves A; Kayani I
Clin Nucl Med; 2017 Jan; 42(1):e1-e7. PubMed ID: 27607161
[TBL] [Abstract][Full Text] [Related]
32. Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices?
Casasnovas RO; Meignan M; Berriolo-Riedinger A; Itti E; Huglo D; Haioun C; Morschhauser F
Curr Hematol Malig Rep; 2012 Sep; 7(3):193-9. PubMed ID: 22723050
[TBL] [Abstract][Full Text] [Related]
33. Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt's lymphoma.
Wei WX; Huang JJ; Li WY; Zhang X; Xia Y; Jiang WQ; Fan W; Li ZM
Chin J Cancer; 2015 Dec; 34(12):608-13. PubMed ID: 26630874
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.
Kostakoglu L; Goy A; Martinelli G; Caballero D; Crump M; Gaidano G; Baetz T; Buckstein R; Fine G; Fingerle-Rowson G; Berge C; Sahin D; Press O; Sehn L
Leuk Lymphoma; 2017 Feb; 58(2):372-381. PubMed ID: 27339738
[TBL] [Abstract][Full Text] [Related]
35. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
[TBL] [Abstract][Full Text] [Related]
36. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
37. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
38. Significance of initial, interim and end-of-therapy
Xie M; Wang L; Jiang Q; Luo X; Zhao X; Li X; Jin J; Ye X; Zhao K
Cancer Cell Int; 2021 Jul; 21(1):394. PubMed ID: 34311728
[TBL] [Abstract][Full Text] [Related]
39. Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study.
Jiang C; Liu J; Li L; Kosik RO; Su M; Zou L; Tian R
Nucl Med Commun; 2017 Nov; 38(11):937-947. PubMed ID: 28858180
[TBL] [Abstract][Full Text] [Related]
40. The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma.
Perry C; Lerman H; Joffe E; Sarid N; Amit O; Avivi I; Kesler M; Ben-Ezra J; Even-Sapir E; Herishanu Y
Medicine (Baltimore); 2016 Mar; 95(9):e2910. PubMed ID: 26945387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
